[go: up one dir, main page]

NL191507B - Afgedichte houder, bevattend een voor injectie gerede zure oplossing, die in hoofdzaak bestaat uit een fysiologisch aanvaardbaar zout van een antracyclineglycoside opgelost in een fysiologisch water bevattend oplosmiddel daarvoor. - Google Patents

Afgedichte houder, bevattend een voor injectie gerede zure oplossing, die in hoofdzaak bestaat uit een fysiologisch aanvaardbaar zout van een antracyclineglycoside opgelost in een fysiologisch water bevattend oplosmiddel daarvoor.

Info

Publication number
NL191507B
NL191507B NL8601698A NL8601698A NL191507B NL 191507 B NL191507 B NL 191507B NL 8601698 A NL8601698 A NL 8601698A NL 8601698 A NL8601698 A NL 8601698A NL 191507 B NL191507 B NL 191507B
Authority
NL
Netherlands
Prior art keywords
injection
acceptable salt
acid solution
consisting essentially
physiologically acceptable
Prior art date
Application number
NL8601698A
Other languages
English (en)
Other versions
NL191507C (nl
NL8601698A (nl
Inventor
Gaetano Gatti
Diego Oldani
Giuseppe Bottoni
Carlo Confalonieri
Luciano Gambini
Ponti Roberto De
Original Assignee
Erba Carlo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10583216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL191507(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Erba Carlo Spa filed Critical Erba Carlo Spa
Publication of NL8601698A publication Critical patent/NL8601698A/nl
Publication of NL191507B publication Critical patent/NL191507B/nl
Application granted granted Critical
Publication of NL191507C publication Critical patent/NL191507C/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
NL8601698A 1985-08-02 1986-06-27 Afgedichte houder, bevattend een voor injectie gerede zure oplossing, die in hoofdzaak bestaat uit een fysiologisch aanvaardbaar zout van een antracyclineglycoside opgelost in een fysiologisch water bevattend oplosmiddel daarvoor. NL191507C (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8519452 1985-08-02
GB858519452A GB8519452D0 (en) 1985-08-02 1985-08-02 Injectable solutions

Publications (3)

Publication Number Publication Date
NL8601698A NL8601698A (nl) 1987-03-02
NL191507B true NL191507B (nl) 1995-04-18
NL191507C NL191507C (nl) 2000-02-16

Family

ID=10583216

Family Applications (2)

Application Number Title Priority Date Filing Date
NL8601698A NL191507C (nl) 1985-08-02 1986-06-27 Afgedichte houder, bevattend een voor injectie gerede zure oplossing, die in hoofdzaak bestaat uit een fysiologisch aanvaardbaar zout van een antracyclineglycoside opgelost in een fysiologisch water bevattend oplosmiddel daarvoor.
NL300011C NL300011I1 (nl) 1985-08-02 2000-07-18 Afgedichte houder, bevattend een voor injectie ge rede zure oplossing, die in hoofdzaak bestaat uit een fysiologisch aanvaardbaar zout van een antracyclineglycoside opgelost in een fysiologisch water bevattend oplosmiddel daarvoor.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NL300011C NL300011I1 (nl) 1985-08-02 2000-07-18 Afgedichte houder, bevattend een voor injectie ge rede zure oplossing, die in hoofdzaak bestaat uit een fysiologisch aanvaardbaar zout van een antracyclineglycoside opgelost in een fysiologisch water bevattend oplosmiddel daarvoor.

Country Status (34)

Country Link
US (1) US4946831A (nl)
JP (1) JPH0655667B2 (nl)
KR (1) KR920001773B1 (nl)
CN (1) CN1064531C (nl)
AT (1) AT397463B (nl)
BE (1) BE905202A (nl)
BG (1) BG60425B2 (nl)
CA (1) CA1291037C (nl)
CH (2) CH668911C1 (nl)
CS (1) CS277561B6 (nl)
CY (1) CY1592A (nl)
DE (1) DE3621844C2 (nl)
DK (1) DK167557B1 (nl)
ES (1) ES8801580A1 (nl)
FI (1) FI86800C (nl)
FR (1) FR2585569B1 (nl)
GB (2) GB8519452D0 (nl)
GR (1) GR861556B (nl)
HK (1) HK93990A (nl)
HU (1) HU196123B (nl)
IE (1) IE59297B1 (nl)
IL (1) IL79129A (nl)
IT (1) IT1204906B (nl)
NL (2) NL191507C (nl)
NO (1) NO170913C (nl)
NZ (1) NZ216604A (nl)
PH (1) PH22332A (nl)
PT (1) PT82865B (nl)
RU (2) RU1837883C (nl)
SE (1) SE466383C (nl)
SG (1) SG80690G (nl)
UA (1) UA29383C2 (nl)
YU (1) YU44788B (nl)
ZA (1) ZA864792B (nl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977082A (en) * 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5124317A (en) * 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.P.A. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5124318A (en) * 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.R.L. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
DE3752368T2 (de) * 1986-12-05 2004-02-12 Pharmacia Italia S.P.A. Doxorubicin enthaltende einspritzbare gebrauchsfertige Lösungen gegen Krebs
FI883338A (fi) * 1987-07-16 1989-01-17 Bristol Myers Co Vattenloesningar av doxorubicinhydroklorid.
FI883337A (fi) * 1987-07-16 1989-01-17 Bristol Myers Co Icke-vattenloesningar av doxorubicinhydroklorin.
DE3801178A1 (de) * 1988-01-18 1989-07-27 Hoechst Ag Stabilisierte trockenzubereitung zytostatisch wirksamer anthracyclin-antibiotika und verfahren zu ihrer herstellung
DE68905577T2 (de) * 1988-12-05 1993-07-01 Bristol Myers Squibb Co Doxorubicin-loesungen.
FI895733A0 (fi) * 1988-12-05 1989-11-30 Bristol Myers Squibb Co Vattenloesningar av doxorubicin.
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
DE19544532C2 (de) * 1995-11-29 1997-12-11 Pharma Dynamics Gmbh Verfahren zum Herstellen eines Doxorubicin-Lyophilisats
PT848009E (pt) * 1996-12-16 2000-11-30 Pharmachemie Bv Processo para a preparacao de epirubicina ou seus sais de adicao de acido a partir de daunorubicina
DE69737510T2 (de) 1996-12-30 2007-12-06 Battelle Memorial Institute, Columbus Verwendung eines unverkapselten Antikrebs-Arzneimittels zur Herstellung einer Zubereitung zur Behandlung von Neoplasmen durch Inhalation
US20090253220A1 (en) * 2003-10-28 2009-10-08 Sukanta Banerjee Absorbing Biomolecules into Gel-Shell Beads
US20070004653A1 (en) * 2005-05-11 2007-01-04 Roberto Arosio Stable lyophilized anthracycline glycosides
JP6138140B2 (ja) * 2011-10-25 2017-05-31 ネクター セラピューティクス 癌患者の治療
CN102614118B (zh) * 2012-03-15 2014-04-30 北京协和药厂 注射用盐酸表柔比星制剂的制备方法及制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
GB1457632A (en) * 1974-03-22 1976-12-08 Farmaceutici Italia Adriamycins
GB1500421A (en) * 1975-01-22 1978-02-08 Farmaceutici Italia Optically active anthracyclinones
US4039663A (en) * 1975-03-19 1977-08-02 Societa' Farmaceutici Italia S.P.A. Daunomycins, process for their uses and intermediates
FR2314726A1 (fr) * 1975-06-16 1977-01-14 Rhone Poulenc Ind Nouveaux derives du naphtagene, leur preparation et les compositions qui les contiennent
GB1511559A (en) * 1975-09-26 1978-05-24 Farmaceutici Italia Anthracycline glycosides
FR2397425A1 (fr) * 1977-07-11 1979-02-09 Rhone Poulenc Ind Nouveaux derives de la daunorubicine, leur preparation et les compositions qui les contiennent
DE2738656A1 (de) * 1977-08-26 1979-03-08 Microbial Chem Res Found Anthracyclinglycoside, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB2007645B (en) * 1977-10-17 1982-05-12 Stanford Res Inst Int Benzyl anthracyclines and pharmaceutical compositions containing them
US4177264A (en) * 1977-10-17 1979-12-04 Sri International N-benzyl anthracyclines
FR2430425A1 (fr) * 1978-07-07 1980-02-01 Rhone Poulenc Ind Nouveaux derives de la daunorubicine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2433027A1 (fr) * 1978-08-08 1980-03-07 Rhone Poulenc Ind Nouveau procede de preparation de derives de la doxorubicine
US4325947A (en) * 1981-05-12 1982-04-20 Farmitalia Carlo Erba S.P.A. 4-Demethoxy-4'-deoxydoxorubicin
US4438105A (en) * 1982-04-19 1984-03-20 Farmaitalia Carlo Erba S.P.A 4'-Iododerivatives of anthracycline glycosides
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
JPS6092212A (ja) * 1983-10-26 1985-05-23 Kyowa Hakko Kogyo Co Ltd ドキソルビシン塩の製剤
DE3752368T2 (de) * 1986-12-05 2004-02-12 Pharmacia Italia S.P.A. Doxorubicin enthaltende einspritzbare gebrauchsfertige Lösungen gegen Krebs

Also Published As

Publication number Publication date
DK306286D0 (da) 1986-06-27
GB8519452D0 (en) 1985-09-11
DE3621844A1 (de) 1987-03-05
NO170913C (no) 2003-10-10
NL191507C (nl) 2000-02-16
AU598197B2 (en) 1990-06-21
ATA176886A (de) 1993-09-15
PT82865A (en) 1986-07-01
CS470886A3 (en) 1992-11-18
AT397463B (de) 1994-04-25
CN1064531C (zh) 2001-04-18
CA1291037C (en) 1991-10-22
YU44788B (en) 1991-02-28
FI862629A0 (fi) 1986-06-19
UA29383C2 (uk) 2000-11-15
RU2110263C1 (ru) 1998-05-10
IT8620917A0 (it) 1986-06-26
IL79129A0 (en) 1986-09-30
NZ216604A (en) 1989-10-27
HK93990A (en) 1990-11-23
PT82865B (pt) 1989-01-17
CH690490C2 (de) 2000-09-29
FI86800B (fi) 1992-07-15
FI86800C (fi) 1999-10-28
ES556291A0 (es) 1988-02-16
SE8602743D0 (sv) 1986-06-19
DE3621844C2 (de) 1994-02-17
ZA864792B (en) 1988-02-24
HUT42326A (en) 1987-07-28
GR861556B (en) 1986-10-17
YU103586A (en) 1988-04-30
FR2585569A1 (fr) 1987-02-06
PH22332A (en) 1988-07-29
JPH0655667B2 (ja) 1994-07-27
KR870001828A (ko) 1987-03-28
SE466383C (sv) 1996-02-19
CY1592A (en) 1992-04-03
RU1837883C (ru) 1993-08-30
NO862587D0 (no) 1986-06-26
CS277561B6 (en) 1993-03-17
GB2178311A (en) 1987-02-11
NL8601698A (nl) 1987-03-02
NO862587L (no) 1987-02-03
SE466383B (sv) 1992-02-10
BE905202A (fr) 1987-02-02
NO170913B (no) 1992-09-21
CH668911C1 (de) 2000-05-31
ES8801580A1 (es) 1988-02-16
NL300011I1 (nl) 2000-10-02
FR2585569B1 (fr) 1990-01-19
GB2178311B (en) 1989-10-11
BG60425B2 (bg) 1995-03-31
SG80690G (en) 1990-11-23
HU196123B (en) 1988-10-28
GB8614800D0 (en) 1986-07-23
US4946831A (en) 1990-08-07
IT1204906B (it) 1989-03-10
DK167557B1 (da) 1993-11-22
SE8602743L (sv) 1987-02-03
CH668911A5 (de) 1989-02-15
FI862629A (fi) 1987-02-03
IE861598L (en) 1987-02-02
IE59297B1 (en) 1994-02-09
IL79129A (en) 1992-03-29
KR920001773B1 (ko) 1992-03-02
CN86104283A (zh) 1987-01-28
DK306286A (da) 1987-02-03
AU5885886A (en) 1987-02-12
JPS6248629A (ja) 1987-03-03

Similar Documents

Publication Publication Date Title
NL191507B (nl) Afgedichte houder, bevattend een voor injectie gerede zure oplossing, die in hoofdzaak bestaat uit een fysiologisch aanvaardbaar zout van een antracyclineglycoside opgelost in een fysiologisch water bevattend oplosmiddel daarvoor.
DE3860550D1 (de) Pharmazeutische zubereitung fuer perkutane verabreichung, die eperison oder tolperison oder eines ihrer salze enthaelt.
NL300045I2 (nl) Fluorcytidine-derivaten, de bereiding daarvan en geneesmiddelen die deze derivaten bevatten.
NL187352B (nl) Farmaceutisch preparaat, alsmede sulfonzuurester van een 2-oxoalkanol derivaat.
NL194719B (nl) Gevormd oraal preparaat voor de geregelde toediening van een nuttig middel aan herkauwers.
NO884820D0 (no) Sementeringspreparat og vandig hydraulisk sementeringsopploesning innbefattende vannopploeselig, ikke-ionisk hydrofobt modifisert hydroksyetylcellulose.
NL194239B (nl) Dialkoxyfosfinolmethylbenzamideverbindingen en farmaceutische preparaten, die deze bevatten.
HUT43953A (en) Process for preparing pharmaceutical comprising etoposid as active substance
NO873534D0 (no) Stabilt farmasoeytisk gelpreparat.
NL192561B (nl) Oogontstekings-werende middelen. Oftalmische preparaten die bepaalde fenylazijnzuurverbindingen bevatten.
ZA90946B (en) Medicament containing dihydrolipoic acid as active substance
DE3852145D1 (de) Indolderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten.
NL193267B (nl) Farmaceutisch preparaat in de vorm van een gelatinecapsule met een vulling die ranitidine-hydrochloride bevat.
IT8812585A0 (it) Preparato, in particolare preparato cosmetico antisolare, nonche' metodo per l'introduzione di una sostanza attiva nella pelle
NL8601837A (nl) Poly-4-aminopyrrool-2-carboxamidoderivaten, werkwijze ter bereiding ervan, farmaceutische preparaten, die deze derivaten bevatten alsmede werkwijze voor de bereiding van de farmaceutische preparaten.
NL950027I1 (nl) Alfa-halogeenmethyl-alfa-aminozuurderivaten en farmaceutisch preparaat die dit bevat.
GB2195221B (en) Process for introducing fish medication into an aqueous environment
ATE58538T1 (de) 4-chinolon-3-carbonsaeurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
IT1182717B (it) Procedimento per ricavare ceftazidima da una sua soluzione acquosa
NL191108C (nl) Farmaceutische waterige cis-platin oplossing.
AR243181A1 (es) Procedimiento de sintesis para obtener nuevos (benzofuran-2-il) imidazoles que tienen actividad farmaceutica y sus sales.
NL192387B (nl) Zuivere silibininederivaten, werkwijze voor de bereiding daarvan en farmaceutisch preparaat dat een dergelijk derivaat bevat.
JPS57146722A (en) Pharmaceutical preparation having improved absorption
AU470093B2 (en) A method for disinfecting human or animal skin
DE3787274D1 (de) Pharmazeutische Präparate, die eine wässerige Lösung eines Pyranoquinolins enthalten.

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
CNR Transfer of rights (patent application after its laying open for public inspection)

Free format text: ERBAMONT INDUSTRIALE S.R.L.

DNT Communications of changes of names of applicants whose applications have been laid open to public inspection

Free format text: ERBA S.R.L. FARMITALIA CARLO -

BC A request for examination has been filed
CNR Transfer of rights (patent application after its laying open for public inspection)

Free format text: PHARMACIA S.P.A.

R1B Notice of opposition during period of laying open

Free format text: PHARMACHEMIE B.V. TE 2031 BP HAARLEM.

DNT Communications of changes of names of applicants whose applications have been laid open to public inspection

Free format text: PHARMACIA & UPJOHN S.P.A.

NP1G Patent granted (not automatically) [patent specification modified]
AC1 Application for a supplementary protection certificate

Free format text: 300011, 20000718

BC1 Further communications concerning applications for a supplementary protection certificate

Free format text: 300011

TNT Modifications of names of proprietors of patents or applicants of examined patent applications

Owner name: PHARMACIA ITALIA S.P.A.

V4 Discontinued because of reaching the maximum lifetime of a patent

Effective date: 20060627